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Abstract
Objectives: Patients with chronic graft-versus-host disease (cGVHD) often suffer from dry mouth and oral mu-
cosal lesions. The primary objective of this study was to investigate the safety of an intra-oral electrostimulator 
(GenNarino) in symptomatic cGVHD patients. The secondary objective was to study the impact on the salivary 
gland involvement of cGVHD patients.
Study Design: This paper presents a case series. The study included patients treated for 4 weeks, randomly as-
signed to the active device and then crossed-over to a sham-device or vice versa. The patients and clinicians were 
blind to the treatment delivered. Data regarding oral mucosal and salivary gland involvement were collected.
Results: Six patients were included in this series. Most of the intraoral areas with manifestations of cGVHD were 
not in contact with the GenNarino device. Two patients developed mild mucosal lesions in areas in contact with 
the GenNarino during the study. However, only one of them had a change in the National Institutes of Health 
(NIH) score for oral cGVHD. The unstimulated and stimulated salivary flow rate increased in 4 out of the 5 pa-
tients included in this analysis. Symptoms of dry mouth and general oral comfort improved.
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Conclusion: This study suggests that GenNarino is safe in cGVHD patients with respect to oral tissues. Furthermore 
the use of GenNarino resulted in subjective and objective improvements in dry mouth symptoms. A large scale study 
is needed to confirm the impact and safety of GenNarino on systemic cGVHD.
Key words: Dry mouth, graft versus host disease, electrostimulation, oral mucosa, hematopoietic stem cell trans-
plantation.
Introduction
Chronic graft-versus-host disease (cGVHD) is a seri-
ous complication of allogeneic hematopoietic stem cell 
transplantation (HSCT). cGVHD is an alloimmune in-
flammatory process, which results from a donor-origin 
cellular response to host tissues (1). cGVHD damages 
both the oral mucosa and the salivary glands. Salivary 
gland involvement in cGVHD is characterized by re-
duced salivary secretion and xerostomia (2-4). Common 
areas of mucosal cGVHD involvement are the tongue, 
buccal and labial mucosae (5,6). The clinical and his-
topathological presentations of salivary cGVHD resem-
ble the changes seen in Sjögren` s syndrome (1). 
Oral moisturizing agents and systemic sialogogues help 
relieve xerostomia. However, the topical preparations 
only provide transient relief and therefore require fre-
quent applications, whereas the systemic agents have 
side effects (7). The search for an optimal treatment 
modality continues.
An intra-oral electro-stimulating device named Gen-
Narino has been introduced recently (8-10). The device 
aims to increase saliva secretion by stimulating fibers 
of the cranial nerves V and VII in the region posterior 
to the lower 3rd molar (10,11). Two multi-center trials 
showed decreased xerostomia and significant improve-
ments in subjective dry mouth symptoms. No significant 
adverse events were reported. Oral mucosal  lesions that 
could be related  to the  use of the device were  observed 
at one follow-up visit in a few patients, but  adjustment 
of the device yielded immediate resolution of the lesions 
(9,10).
Most of the reports on GenNarino refer to its use in 
patients suffering from dry mouth due to Sjögren` s 
syndrome, radiation induced salivary gland damage or 
drug-induced hyposalivation. Although all these pa-
tient populations are similar to GVHD patients regard-
ing signs and symptoms of dry mouth, the underlying 
characteristics of GVHD patients raise important safety 
concerns, specifically:
1. In cGVHD patients the oral mucosa may be severely 
involved with areas of erythema, lichenoid, ulceration 
or mucoceles. cGVHD symptoms may deteriorate when 
the patient experiences stress of any nature e.g. emo-
tional or physical stress due to mechanical injury which 
the device may cause.
2. Patients with cGVHD have a fragile immune system, 
causing fluctuations in their general health status. These 
patients are hospitalized repeatedly due to systemic in-
fections and their complications. Potentially, the inci-
dental peaks of systemic illness may over-ride the base-
line effects of local electro-stimulation. Hypothetically, 
the intra-oral electrostimulator may cause stress to the 
patient and trigger or exacerbate systemic symptomatic 
cGVHD.
In this study we will describe the effect of the intra-oral 
electrostimulator in a series of oral cGVHD patients. 
The primary objective was to assess the effects on the 
oral mucosa (safety) and the secondary objective was 
to study the impact on the salivary gland involvement 
of cGVHD patients (efficacy). Part of the data for some 
of the patients reported here were included in a previ-
ous article about a multi-center study (9). The sample 
described in this study includes additional patients. The 
response of the oral mucosa in cGVHD patients has not 
been previously reported. 
Patient and Methods
Device description
The intraoral electrostimulation device consists of a 
mouth piece made to fit the mandibular dental arch and 
an infrared remote control (Fig. 1). It contains an elec-
tronic circuit (with a microprocessor and a receiver of 
remote control signals), a pair of stimulating electrodes, 
and a battery. The electrodes directly contact the oral 
mucosa in the mandibular third molar area, in proxim-
ity to the lingual nerve; therefore no conductive gel is 
needed. The patient activates and deactivates the elec-
Fig. 1. The device is fabricated individually to lie on the 
lower dentition loosely. The electric circuit is embedded in 
the acrylic body. The stimulating electrodes are positioned 
in the area of the mandibular third molar, in proximity to 
the lingual nerve.
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trical stimulation by pressing the “on” and “off” but-
tons on the remote control, respectively. The intensity 
of the electrical current is so low that it is not felt by the 
patient. An amber light on the intra-oral device blinks 
upon activation of the remote control to show that the 
device received the signal from the remote; devices 
were replaced if the light did not blink. The amber light 
responded in the same way in the sham remotes.
Study design
A series of 6 oral cGVHD patients is presented. Gene-
rally, the study design was a sham-controlled, cross-over 
randomized, double blind study. It was approved by the 
hospital ethics committee and conducted in accordance 
with the Declaration of Helsinki. At the baseline visit all 
participants signed an informed consent form, demo-
graphic data and medical background were recorded, 
patients were evaluated clinically (see Clinical Evalua-
tion), and impressions for custom made GenNarino de-
vices were taken. The patients were provided with one 
GenNarino device, and two identical remote controls, 
one that switched GenNarino on and off (active arm), 
and a second that had no effect (sham arm). Each remote 
control was used for four weeks in an order determined 
by a randomized schedule. In the active state the device 
emitted electrical stimuli which were below the thresh-
old of tactile sense, while in the sham state the device did 
not emit any electrical stimuli. In both arms the foreign 
body, i.e. the device, exerted mechanical stimuli in the 
oral cavity (see Device Description below). The device 
was delivered after baseline measurements were taken. 
On visit 2, one month later, the remotes were swapped. 
Visit 3 took place one month later. The patients and 
the investigators were blind regarding the type of the 
remote control (active/sham). Safety analysis included 
data from all patients for all visits. 
Due to the fact that very few patients were recruited, 
the comparative aspect of the study was reduced and 
data are presented as a case-series. The data referring 
to oral mucosal response to the intra-oral electrostimu-
lator and the safety are very important and have been 
summarized.
Inclusion and exclusion criteria
Subjects were included if they were post allogeneic 
HSCT, had cGVHD and xerostomia and signed the in-
formed consent form. Patients were excluded if they 
met the following criteria: 1) younger than 18 years old; 
2) seropositive for human immunodeficiency virus or 
hepatitis C virus; 3) wearing pacemakers or defibrilla-
tors; 4) allergy to the materials used in the electrostimu-
lation device; 5) mental disease or depression; 6) preg-
nancy; 7) chronic or recurrent, erosive or ulcerative, or 
premalignant or malignant oral lesions (except for oral 
cGVHD); 8) oral anatomic characteristics precluding 
the use of the device; and 9) edentulous condition den-
tal implants that could support the GenNarino would 
considered equivalent to teeth. Patients taking bisphos-
phonate drugs before and during the trial were excluded 
due to the unknown risk of osteonecrosis of the jaws 
following electrostimulation. 
Patients taking systemic sialagogues were asked to 
discontinue their medication during the trial. Dosage 
of systemic immunosuppressive medications was un-
changed during the study period in order to avoid po-
tential alterations in salivary flow rates.
Clinical evaluation
At all three visits a clinical examination was preformed, 
questionnaires were administered, and safety-related 
information was obtained. 
The clinical examination included scoring oral cGVHD 
according to the NIH scale (12). Analysis referred to the 
total severity score as well as to the type of cGVHD-re-
lated oral manifestations present (lichenoid, erythema, 
ulceration and mucocele) and the cGVHD distribution 
(lip, labial mucosa, buccal mucosa, tongue and soft 
palate). In addition cGVHD signs were categorized ac-
cording to the surfaces in contact with the GenNarino 
(oral mucosa not in contact with the GenNarino, oral 
mucosa in contact with the GenNarino except the elec-
trodes, oral mucosa in contact with the electrodes). Oral 
mucosal lesions which were not attributed to cGVHD 
were also documented. The oral evaluation included 
sialometry. Unstimulated sialometry was conducted for 
5 minutes while the patient was at rest. For stimulated 
sialometry, the patient chewed a standard piece of para-
film for 10 minutes, and saliva was collected during the 
last five minutes of chewing. Saliva volume was deter-
mined gravimetrically (13).
The patients filled in a questionnaire about symptoms 
related to dry mouth and quality of life. Questions were 
about the level of “dry mouth”, “mouth comfort”, “dif-
ficulty while speaking”, “difficulty while swallowing”, 
and “quality of life” (QoL). Answers were reported us-
ing 100-mm visual analog scales (VAS) from the worst 
on the left to the best on the right.
The safety-related outcome measures included vital 
signs and changes in general health, which were as-
sessed at each visit. Any discomfort caused by the elec-
trostimulation device and any adjustments needed were 
recorded.
Statistical analysis
Due to the small sample size, only descriptive statistics 
were performed. The rate of positive events (i.e. find-
ings compatible with oral cGVHD) was calculated.
Results
Patients 
Nine patients were screened. Two were excluded due 
to bisphosphonate treatment and one was excluded be-
cause they were unable to attend all the requisite vis-
its. The medical history and basic efficacy parameters 
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are described for each of the 6 cGVHD patients in the 
study followed by detailed descriptions of the primary 
outcomes of this study, namely, the safety parameters 
related to oral cGVHD. 
Case 1
A 31-year-old male with a history of Non-Hodgkin Lym-
phoma (NHL), conditioned with fludarabine, busulfan 
and total body irradiation following HSCT (reduced in-
tensity protocol), developed cGVHD including a com-
plaint of dry mouth. At 57 months after HSCT he was 
enrolled in the study. Before using the electrostimulator 
his only medication was oxazepam. 
After GenNarino use the oral mucosal cGVHD lesions 
were only on surfaces not in contact with the device. 
The NIH score increased slightly after the active treat-
ment (Table 1).
The patient’s score for “dry mouth” and “general mouth 
comfort” improved after application of the GenNarino, 
with better results from the active device (Table 2). The 
categories “difficulty while speaking”, “difficulty while 
swallowing” and QoL did not improve.
Sialometry had mixed results (Table 2). Baseline read-
ings were 0.392 and 1.372 ml/min for unstimulated and 
stimulated sialometry, respectively. After the active 
device was used, the unstimulated salivary flow was 
unchanged and the stimulated sialometry increased by 
12% compared to baseline. After the sham treatment in 
the second month the unstimulated secretion increased 
in 40% and the stimulated secretion decreased 33% 
compared to baseline. 
Case 2
A 68-year-old man with a history of hypertension and 
Acute Myelogenous Leukemia (AML) for which he un-
derwent allogeneic HSCT was referred for experimen-
tal treatment with GenNarino. The conditioning for the 
HSCT was of reduced intensity and included fludarabine 
and busulfan. Following HSCT he developed cGVHD 
including symptomatic salivary gland involvement. At 
nine months following the HSCT he started treatment 
with the GenNarino. At the start of the protocol his 
medications included cyclosporine A, zolpedim, meto-
propol, acyclovir, cilazapril, and sulfametaxazole.
Oral mucosal cGVHD involvement was only on surfaces 
not in contact with the device. The NIH score decreased 
with time, more so after the active device was used.
According to the patient’s questionnaire, “general 
mouth comfort” improved (Table 2). Other questions 
did not show subjective improvement.
At baseline the unstimulated and stimulated salivary 
flow were 0.048 and 0.184 ml/min, respectively (Table 
2). After the sham treatment, during the second month 
the unstimulated secretion increased by 29% and stimu-
lated secretion increased by 12% compared to the base-
line. Following use of the active device the unstimulated 
salivary increased by 717% and the stimulated sialom-
etry increased by 737% compared to the baseline. The 
patient did not use any saliva substitutes or saliva stimu-
lants (chewing gum) during this period.
Case 3
A 66-year-old man presented with a complaint of dry 
mouth 8 months after allogeneic HSCT. His medical 
history included AML. The reduced-intensity condi-
tioning for the HSCT included fludarabine and busul-
fan. He had no other co-morbidities. At the beginning of 
the study his medications were omeprazole, miodarone 
hydrochloride, tacrolimus, acyclovir, folic acid, warfa-
Pt. No. 
Oral
GVHD
Not in contact with 
GenNarino
In contact with 
GenNarino’s acrylic 
base 
In contact with 
GenNarino´s
electrodes 
NIH score 
Visit * Base A P Base A P Base A P Base A P
1 Y Y Y N N N N N N 0 2 NA 
2 Y Y Y N N N N N N 7 4 6
3 Y Y N N Y Y Y Y Y 8 8 12
4 Y Y Y N Y Y N N N 2 NA 2
5 Y Y Y Y NA NA N Y Y 2 4 4
6 Y Y Y Y N Y N N N 2 1 5
Total positive tests Mean ± SD 
Rate of involvement 
during active and sham 
treatment periods 
11/12 5/10 4/12
3.5 ± 3.21 3.8 ± 2.7 5.8 ± 3.8 
Median (Range) 
2 (0-8) 4 (1-8) 5 (2-12) 
Table 1. Mucosal Oral cGVHD manifestations per visit.
Pt. No. – patient number, Base – baseline visit, A – at the end of the active treatment (mechanical and electric stimulation), P – at the end of 
the sham treatment (mechanical stimulation only), Y – yes, N – no, NA – not available, NIH – National Institute of Health.
* Active device was used in the first month in patients #1,2,3. Active device was used in the second month in patients #4,6.
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rin, vitamin B, magnesium, imunoglubolin normal hu-
man, and sulphamethoxazole/trimethoprim.
The oral mucosal cGVHD was relatively severe at 
baseline with a NIH score of 8. Oral cGVHD did not 
change after active treatment and deteriorated after the 
sham treatment (Table 1). This deterioration was part 
of an episode of severe systemic cGVHD (see Safety 
Parameters).
Four out of the 5 subjective parameters improved af-
ter the active treatment, including “dry mouth”, “gen-
eral mouth comfort”, “difficulty while swallowing” and 
QoL (Table 2). 
At baseline the unstimulated and stimulated salivary 
flow were 0.11 and 0.824 ml/min, respectively (Table 2). 
After active treatment unstimulated salivary flow rate in-
creased by 60% and the stimulated sialometry increased 
by 35% compared to baseline. After the sham treatment 
during the second month unstimulated secretion increased 
by 13% and stimulated secretion decreased by 32%. 
Case 4
A 51-year-old man with a history of hypertension and 
NHL, for which he underwent allogeneic HSCT, was 
referred 34 months post-HSCT with a complaint of 
dry mouth. The reduced-intensity conditioning for the 
HSCT included fludarabine, busulfan and ATG. He de-
veloped cGVHD and was treated with cyclosporine A, 
ramipril, omeprazole, prednisolone, dapsone, acyclovir, 
fluconazole, ursodeoxycholic acid.
The oral cGVHD score seemed to be stable before and 
after the sham treatment with GenNarino. Lesions ap-
peared in areas in contact with the device (Table 1).
Three subjective parameters improved, including “dry 
mouth”, “general mouth comfort” and “difficulty while 
swallowing” (Table 2). The improvement was greater 
after sham treatment than after active treatment.
At baseline the unstimulated and stimulated salivary 
flow were 0.106 and 0.472 ml/min, respectively (Table 
2). The sham treatment was used first. After the sham 
treatment the unstimulated secretion decreased by 4% 
and the stimulated secretion increased by 9%. After ac-
tive treatment the unstimulated and stimulated salivary 
increased by 8% and 83%, respectively.
Case 5
A 36 year-old man suffering from dry mouth was re-
ferred to our clinic. He was diagnosed with Acute Lym-
phoblastic Leukemia (ALL) for which he underwent 
allogeneic HSCT. Data about the conditioning regimen 
was not available as transplantation was carried out in 
a different country. His medical background included 
asthma and cGVHD. At the start of the study, 71 months 
after HSCT, he was medicated with omeprazole, pred-
nisone and ursodeoxycholic acid.
When the randomization key was opened, we discov-
ered that the randomization data of patient #5 was miss-
ing; therefore only the results for oral cGVHD, relevant 
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to device safety were included. Sialometry data were 
not analyzed.
Generally the NIH score increased after the use of the 
electrostimulator. Oral mucosal cGVHD was present 
prior to the application of the GenNarino on surfaces 
not in contact with the device and appeared in areas in 
contact with the electrodes. The patient tolerated the 
treatment well.
Case 6
A 64-year-old female with a history of HTN, hypothy-
roidism and AML enrolled in the study. She underwent 
allogeneic HSCT 124 months prior to initiation of the 
GenNarino treatment. Upon initial examination medi-
cations were simvastatin, nifedipine, levothyroxine so-
dium, sulfametaxazole, prednisolone and pilocarpine 
hydrochloride. She stopped using pilocarpine in order 
to follow study protocols.
Oral mucosal cGVHD was mostly in areas not in con-
tact with the GenNarino. The NIH score fluctuated dur-
ing the periods of sham/active treatment.
Patient reported “dry mouth”, “general mouth comfort” 
and “difficulty while swallowing” to be better after ac-
tive treatment (Table 2). 
At baseline the unstimulated and stimulated salivary 
flow were 0.036 and 1.514 ml/min, respectively (Table 
2). The sham treatment was used in the first month. Af-
ter the sham treatment the unstimulated secretion in-
creased by 758% and the stimulated secretion decreased 
by 53%. After the active treatment the unstimulated 
salivary flow increased by 889% and the stimulated 
salivary flow decreased by 57%. The patient did not 
use any saliva substitutes or saliva stimulants (chewing 
gum) during this period.
Oral mucosal cGVHD
Lichenoid was the most common type of lesion found in all 
patients at all visits. Erythema was the second most com-
mon type of manifestation presenting in 57.1% of visits in 
3 patients. Ulceration was observed in 55.5% of the evalu-
ations in 3 patients. Mucoceles were not observed.
The signs of oral mucosal cGVHD were mostly on the 
buccal mucosa (100% of patients), tongue, labial mu-
cosa and lips (each in 20% of patients). The soft palate 
was only involved in one patient.
The most severe cGVHD score, based on the NIH scale, 
was observed following sham treatment (Table 1).
Most of the oral manifestations of cGVHD were not on 
surfaces in contact with the GenNarino (Table 1). Four 
patients had oral cGVHD signs in areas touching the 
GenNarino. Two of them developed these lesions dur-
ing follow-up. The lowest rate of oral cGVHD signs was 
noted on the mucosal surface in contact with the elec-
trodes presenting in 2 patients. There was no clear trend 
during the trial for increasing or decreasing cGVHD 
manifestations in areas in contact with the device. The 
only non-cGVHD oral lesion recorded during the study 
was gingivitis (patient #1). This patient had poor oral 
hygiene which did not improve despite repeated oral hy-
giene instruction.
Safety parameters
No patients complained about oral pain, feeling the elec-
tric stimulus or a burning sensation in the oral tissues. 
At the end of the trial, one patient (patient #1) reported 
that the device made him feel nauseous. It is worth men-
tioning that this patient suffers from dentophobia and 
has a very sensitive gag reflex that may be the cause of 
his complaint.
Two patients were hospitalized. These serious adverse 
events (SAE) were classified as not-related to the study-
device. The first SAE (patient #5) was septic arthritis in 
the right knee and left elbow one week after the study 
ended, the patient complained of knee pain and swelling, 
he was afebrile during hospitalization. He was treated 
empirically with cefamezine and rocacefine which were 
switched to penbritin and gentamycin when group B 
streptococcus was isolated from blood and knee sam-
ples. His condition improved and he was referred for 
physiotherapy. The second SAE (patient #3) was a dete-
rioration of systemic cGVHD, mostly in the liver, dur-
ing the study. The patient was treated with prednisone, 
tacrolimus, ursodeoxycholic acid and supportive care 
and responded well. The patient did not continue to par-
ticipate in the study due to this SAE.
Discussion
cGVHD affects numerous target organs including the 
oral mucosa with fluctuating severity, depending on re-
sponses to specific triggers. Therefore, if an intraoral 
electrostimulator is to be used to relieve xerostomia 
among cGVHD patients, it must not exacerbate symp-
toms of oral mucosal and systemic cGVHD. Conse-
quently, our main objective was to assess the effect of 
GenNarino on oral mucosal cGVHD and safety param-
eters. The results of this study show that GenNarino is 
safe. No severe adverse oral events were reported. After 
deleting the data of the patient that presented unstable 
systemic cGVHD, the NIH score for oral cGVHD at 
baseline and following the active treatment with the 
electrostimulator was similar. Furthermore, the distri-
bution of oral manifestations of cGVHD was typical to 
the presentation of oral cGVHD that is reported in the 
literature with a slight increase in the rate of involve-
ment in areas contacting the device (2 out of 5 patients 
developed mild involvement on new areas e.g. mild ery-
thema). In other words, GenNarino did not trigger or 
aggravate oral cGVHD.
The systemic severe adverse events documented in-
cluded infection and deterioration of systemic cGVHD. 
Infection is a common complication in post-HSCT pa-
tients because of their underlying immunosuppression. 
The cause of the deterioration in the systemic GVHD 
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in second case of SAE was unclear; these episodes may 
arise due to emotional, physical or pathological triggers. 
This particular episode was serious, and the patient was 
given high dose steroids; during recovery, the complaint 
of dry mouth also resolved.
The efficacy of this treatment for dry mouth was sug-
gested by the results of sialometry and subjective tests. 
Salivary flow rate increased in 4 out of 5 patients using 
the active device. All patients reported improvement 
in “dry mouth”, and oral “general comfort” levels and 
some improvement in “difficulty while swallowing”. 
However, no improvements were seen in other subjec-
tive parameters “difficulty while speaking” and general 
QoL. These findings were not surprising since numer-
ous factors influence swallowing, speaking and general 
QoL, such as oro-pharyngeal mucosal status in cGVHD 
patients and concurrent systemic debilitating conditions. 
Unfortunately the patient sample was too small to cal-
culate statistical significance. However, our descriptive 
findings support the literature regarding GenNarino for 
the treatment of drug induced dry mouth and Sjögren’s 
syndrome (8,14) .
According to the International Consensus organized by 
Germany, Austria and Switzerland (15) and the NIH 
Consensus Development Project on Criteria for Clinical 
Trials in cGVHD (16), cGVHD-related salivary gland in-
volvement may be treated with saliva substitutes or sial-
ogogues. These recommendations are based on success-
ful treatment with pilocarpine (17) and cevimeline (18) 
demonstrated in open trials on samples the same size as 
the current study. Furthermore, the randomized control-
led trial that evaluated the efficacy of pilocarpine for the 
treatment of cGVHD was inconclusive (19). Considering 
that cGVHD patients are frequently treated with numer-
ous medications the addition of a systemic pharmaco-
logic agent to manage dry mouth may put the patient at 
risk for systemic, drug related adverse events. Therefore, 
pharmacologic agents for salivary gland cGVHD are not 
an ideal treatment and the advantages of a non-pharma-
cological treatment delivered by an intra-oral device, 
with no systemic side effects, are clear.
Obviously, supportive measures to prevent damage to 
the teeth (e.g. rampant caries) caused by xerostomia 
are part of the protocol in patients with salivary gland 
cGVHD (15,16). These measures include frequent fluo-
ride application and the use of a salivary stimulant (such 
as chewing sugar-free gum). 
We planned for a larger patient enrollment in the study, 
however these patients are medically complex, and since 
dry mouth is not lethal, the low priority the patient’s 
placed on our trial is understandable. 
In summary, this case series suggests that GenNarino is 
safe in oral cGVHD patients. Furthermore, in this group 
of patients the use of GenNarino resulted in subjective 
and objective improvements in dry mouth symptoms. 
The effects of GenNarino on systemic GVHD need to 
be addressed in a large-scale study.
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